Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Annals of Oncology

Volumn 28, Issue 2, 2017, Pages 368-376

  Menzies, Alexander M ^a,b   Johnson, D B ^c   Ramanujam, S ^a   Atkinson, V G ^d   Wong, A N M ^e   Park, J J ^f   McQuade, J L ^g   Shoushtari, A N ^h   Tsai, K K ⁱ   Eroglu, Z ^j   Klein, O ^k   Hassel, J C ^l   Sosman, J A ^c   Guminski, A ^a,b   Sullivan, R J ^m   Ribas, A ⁿ   Carlino, M S ^a,f   Davies, M A ^g   Sandhu, S K ^e   Long, G V ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Royal North Shore and Mater Hospitals   (Australia)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f Crown Princess Mary Cancer Centre Westmead   (Australia)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k AUSTIN HEALTH   (Australia)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Autoimmune disorder; Autoimmunity; Cancer; Immunotherapy; Melanoma; PD 1

Indexed keywords

IPILIMUMAB; LACTATE DEHYDROGENASE; NIVOLUMAB; PEMBROLIZUMAB; PREDNISONE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER PROGNOSIS; COLITIS; CONSERVATIVE TREATMENT; CROHN DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEPATITIS; HUMAN; HYPOPHYSITIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SKIN DISEASE; THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; SKIN TUMOR; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; AUTOIMMUNE DISEASES; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; YOUNG ADULT;

EID: 85019333926     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw443     Document Type: Article

References (22)

1. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34.
2. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532.
3. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330.
4. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135.
5. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639.
6. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028.
7. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2015; 387(10027): 1540-1550.
8. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803-1813.
9. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-319.
10. Weber JS, Kudchadkar RR, Yu B et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol 2013; 31: 4311-4318.
11. Johnson DB, Sullivan RJ, Ott PA et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016; 2: 234-240.
12. Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res 2012; 32: 1119-1136.
13. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
14. Services UDoHaH. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. US Department of Health and Human Services, 2009. http://evs.nci. nih.gov/ftp1 /CTCAE/CTCAE_4.03_2010-06-14_ QuickReference:8.5x11.pdf (29 June 2015, date last accessed).
15. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
16. Raptopoulou AP, Bertsias G, Makrygiannakis D et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum 2010; 62: 1870-1880.
17. Kobayashi M, Kawano S, Hatachi S et al. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjogren's syndrome. J Rheumatol 2005; 32: 2156-2163.
18. van den Berg B, Walgaard C, Drenthen J et al. Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014; 10: 469-482.
19. Weber JS, Antonia SJ, Topalian SL et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis. ASCO Meet Abstr 2015; 33: 9018.
20. Daud A, Ribas A, Robert C et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. ASCO Meet Abstr 2015; 33: 9005.
21. Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908-918.
22. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-384.